- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03923686
Lumen-apposing Metal Stent With or Without Coaxial Plastic Stent for Treatment of Walled-off Pancreatic Necrosis
Endoscopic Ultrasound-guided Drainage Using Lumen-apposing Metal Stent With or Without Coaxial Plastic Stent for Treatment of Walled-off Pancreatic Necrosis: a Prospective Randomised Study
Study Overview
Status
Intervention / Treatment
Detailed Description
The aim of the study is to compare endoscopic ultrasound guided transmural drainage using lumen-apposing metal stent with (1.) or without (2.) coaxial plastic stent in the management of walled-off pancreatic necrosis. The usage of LAMS has been evaluated as a safe and effective method for the drainage of walled-off pancreatic necrosis in various studies. However, complications such as bleeding, infection due to stent obstruction, stent migration, or buried stent syndrome have been reported. A preventive measure to minimize adverse events related to LAMS insertion by means of placing an anchoring DPS through the LAMS have been suggested but there has been no prospective randomized study to assess the utility of such measure to date.
The study is to be conducted at a tertiary institution with an expertise in treating hepato-pancreato-biliary diseases. The main timeframe of the study is 3 weeks following LAMS insertion with or without DPS. All LAMS will be extracted 3 weeks after the initial procedure. The extraction will be preceded by a CT scan of the abdomen to assess whether the DPS needs to be left in place/ inserted in patients with incomplete resolution of the collection. In addition, material from the collection will be collected for cultivation at every endoscopic intervention to assess colonization by microbial flora over time. All patients will be closely followed with clinical, laboratory, and radiological assessment for 12 months in total.
Our experience has shown failure of the (2.) method in 70 % of patients so far. Assuming a clinically significant difference to be a reduction to 40 % in failed patients using the (1) method, the required study population size was calculated to 62 patients (31 in both arms) by power analysis (at standard alpha and beta values). The final number was set to 70 as a safety measure.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Olomouc, Czechia, 77900
- University Hospital Olomouc, Second Department of Internal Medicine - Gastroenterology and Geriatrics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- walled-off pancreatic necrosis (WON) indicated for endoscopical drainage
- signed informed consent form
Exclusion Criteria:
- patient disagreement with the study
- types of collections other than WON
- drainage with stents other than LAMS
- previous attempts at drainage of WON
- severe coagulopathy or thrombocytopenia
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: LAMS plus DPS
Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) with coaxial double-pigtail plastic stent (DPS).
|
Endoscopic ultrasound-guided drainage using lumen-apposing metal stent with coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
|
Active Comparator: LAMS alone
Endoscopic ultrasound-guided (EUS) transmural drainage of walled-off pancreatic necrosis (WON) using lumen-apposing metal stent (LAMS) alone.
|
Endoscopic ultrasound-guided drainage using lumen-apposing metal stent without coaxial plastic stent in the treatment of walled-off pancreatic necrosis.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Failure of method
Time Frame: up to 1 month
|
Defined as a necessity of re-intervention (endoscopic, surgical, percutaneous) within the period following LAMS insertion and before its planned extraction due to complications related to LAMS insertion and/or clinical deterioration.
|
up to 1 month
|
Mortality
Time Frame: up to 12 months
|
Overall mortality during subsequent follow-up
|
up to 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical success rate
Time Frame: up to 1 month
|
Resolution of the collection and symptoms following endoscopic drainage with LAMS before its extraction.
|
up to 1 month
|
Adverse events
Time Frame: up to 1 month
|
Primarily complications caused by LAMS itself (bleeding due to vessel erosion, secondary infection due to stent obstruction, stent migration, buried stent syndrome).
|
up to 1 month
|
Number of procedures
Time Frame: up to 1 month
|
Number of forced endoscopic interventions (direct endoscopic necrosectomy, debridement, desobliteration, etc.) required to achieve resolution.
|
up to 1 month
|
Hospital stay
Time Frame: up to 1 month
|
Total length of hospital stay within the period following LAMS insertion until its extraction.
|
up to 1 month
|
Recurrence rate
Time Frame: up to 12 months
|
Recurrence of the collection accompanied by symptoms provided there had been previous clinical success with documented resolution of the collection by radiological studies.
|
up to 12 months
|
Microbiological cultivation
Time Frame: up to 1 month
|
Material from the collection will be collected at every endoscopic intervention (at least during insertion and extraction of LAMS) to assess colonization by microbial flora over time.
|
up to 1 month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Petr Vanek, MD, Assistant Professor, physician
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FNOL 2IK 001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatitis, Acute Necrotizing
-
Centre Hospitalier Universitaire de NiceRecruiting
-
Tianjin Nankai HospitalCompletedAcute PancreatitisChina
-
Northern State Medical UniversityCompleted
-
Erzhen ChenRenJi HospitalUnknownPancreatitis,Acute NecrotizingChina
-
Orlando Health, Inc.Mayo Clinic; University of Alabama at Birmingham; University of Southern California and other collaboratorsActive, not recruitingPancreatitis,Acute NecrotizingUnited States
-
University of OuluCopenhagen University Hospital, HvidovreUnknownAcute Necrotizing PancreatitisFinland
-
Sichuan Academy of Medical SciencesPeking Union Medical College HospitalCompleted
-
John Gasdal KarstensenCompleted
-
Asian Institute of Gastroenterology, IndiaCompletedAcute Pancreatitis NecrotizingIndia
-
Postgraduate Institute of Medical Education and...RecruitingAcute Necrotizing PancreatitisIndia
Clinical Trials on EUS-guided drainage using LAMS with DPS
-
McGill University Health Centre/Research Institute...Completed
-
Asan Medical CenterCompletedCholecystitisKorea, Republic of
-
Chinese University of Hong KongSoonChunHyang University School of MedicineCompletedAcute Cholecystitis | Pancreatic Pseudocyst | Biliary Obstruction | Pancreatic NecrosisChina
-
Hospital Universitario Virgen MacarenaDelos ClinicalUnknownMalignant Ascites
-
Institut Paoli-CalmettesCompletedJaundiceFrance, Monaco
-
Inje UniversityCompletedNeoplasms | Bile Duct Obstruction | Disorder of Bile Duct StentKorea, Republic of
-
John Gasdal KarstensenCompleted
-
Johns Hopkins UniversityMedical University of South Carolina; University of Colorado, Denver; All India... and other collaboratorsCompletedMalignant Distal Biliary ObstructionUnited States, India, Japan, Italy, Netherlands
-
Arcispedale Santa Maria Nuova-IRCCSCompletedPancreatic Cancer | Obstructive Jaundice
-
Prince of Songkla UniversityTerminatedMalignant Biliary StrictureThailand